Characterization and evaluation of dermatological immune-mediated reactions associated with checkpoint inhibitors: an observational, longitudinal and retrospective study in an oncology service in Salvador/BA
DOI:
https://doi.org/10.30968/rbfhss.2024.152.1129Abstract
Objective: To evaluate dermatological immune-mediated reactions in patients treated with checkpoint inhibitors at an oncology center in Salvador-BA. Method: An observational, longitudinal, retrospective, descriptive, and uncontrolled study was carried out in patients undergoing treatment with checkpoint inhibitors, during the period from Jan/2021 to Dec/2021. After applying the exclusion criteria, the study’s sample size resulted in 69 patients. Electronic spreadsheets from the Excel tool (Microsoft®) were used for data processing and statistical analysis. The identification and measurement of the severity of toxicities followed the Common Toxicity Criteria, as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Results: The investigation found 84 immunemediated dermatological reactions occurring in 44 patients (63.77%), with the most frequent being dry skin (37%), maculopapular rash (26%), and itching (20%).The regimen with the highest incidence of reactions was the one that included pembrolizumab, with 47 occurrences. The severity of dermatological immune-mediated toxicities ranged from grade 1 to grade 2, indicating a good safety profile for these medications. Key management strategies included the use of emollients, increased fluid intake, and administration of antihistamines and corticosteroids. Conclusion: The findings of this study are aligned with the evidence from the clinical literature and highlight the importance of in-depth understanding of factors related to immunotherapy toxicity, in order to detect these reactions prematurely, optimizing management and preventing more serious complications.
Downloads
References
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 2017; 5 (1): 95. DOI: 10.1186/s40425-017-0300-z
Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci, 2018; 22 (12): 3855-3864. DOI:10.26355/eurrev_201806_15270
Kumar V, Chaudhary N, Garg M, et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol, 2017; 8 (49): 14. DOI: 10.3389/fphar.2017.00049
Ellis SR, Vierra AT, Millsop JW, et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol, 2020; 83 (4): 1130-1143. DOI: 10.1016/j.jaad.2020.04.105
Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6 (8): 1-18. DOI: 10.1186/s40425-018-0316-z
Loqtorzi®: solução injetável. Redwood City: Coherus BioSciences. [bula de medicamento]. 2023: 26. Available in: https://www.coherus.com/. Accessed on: 19st Dez 2023.
Zynyz®: solução injetável. Wilmington: Incyte Corporation. [bula de medicamento]. 2023: 20. Available in: https://incyte.com/. Accessed on: 19st Dez 2023.
Jemperli®: Solução para diluição. Responsável técnico Rafael Salles de Carvalho. Rio de Janeiro: GlaxoSmithKline Brasil Ltda. [bula de medicamento]. 2023: 15. Available in: https://br.gsk.com/. Accessed on: 19st Dez 2023.
Gault A, Anderson AE, Plummer R, et al. Cutaneous imune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol, 2021; 185 (2): 263–271. 021. DOI: 10.1111/bjd.19750
Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor: related dermatologic adverse events. J Am Acad Dermatol, 2020; 83 (5): 1255-1268. DOI: 10.1016/j.jaad.2020.03.132
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol, 2015; 26 (12): 2375-2391. DOI: 10.1093/annonc/mdv383.
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 2013; 369 (2):122–133. DOI: 10.1056/NEJMoa1302369
Al-salama ZT. Durvalumab: A Review in Extensive-Stage SCLC. Target Oncol, 2022; 16 (6): 857–864. DOI: 10.1007/s11523-021-00843-0
Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors. Am J Clin Dermatol, 2017; 19 (3): 345–361. DOI: 10.1007/s40257-017-0336-3
Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res, 2015; 4 (5): 560–575. DOI: 10.3978/j.issn.2218-6751.2015.06.06
Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. National Institutes of Health National Cancer Institute. [s.l: s.n.]. Available in: <https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf>. Accessed on: 10st Dez 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
